{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:23:08Z","timestamp":1759580588768},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.08.002","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"445-454","source":"Crossref","is-referenced-by-count":9,"title":["New targets for Ph+ leukaemia therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Giovanni","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.08.002_bib1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.08.002_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol"},{"issue":"18S","key":"10.1016\/j.beha.2009.08.002_bib3","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2006.24.18_suppl.6506","article-title":"Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study","volume":"24","author":"Druker","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.08.002_bib4","first-page":"1179","article-title":"Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro","volume":"56","author":"Fidanza","year":"1996","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.beha.2009.08.002_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Arico","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2009.08.002_bib6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib7","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2009.08.002_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.002_bib9","first-page":"1084","article-title":"High-resolution genomic profiling of Ph-positive acute lymphoblastic leukaemia (ALL) identified recurrent copy number anomalies in genes regulating the cell cycle and the B-cell differentiation","volume":"93","author":"Iacobucci","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib10","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.4049\/jimmunol.169.11.6594","article-title":"Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells","volume":"169","author":"Cerutti","year":"2002","journal-title":"J Immunol"},{"issue":"24","key":"10.1016\/j.beha.2009.08.002_bib11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2009.08.002_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib13","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7001","article-title":"Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"26","author":"Bruemmendorf","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2009.08.002_bib15","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib16","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2009.08.002_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.002_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.7.7","article-title":"Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph? Acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205","author":"Foa","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2009.08.002_bib19","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2009.08.002_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2001-12-0371","article-title":"MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia","volume":"100","author":"Tafuri","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.002_bib21","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2009.08.002_bib22","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.beha.2009.08.002_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2009.08.002_bib24","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML","volume":"104","author":"O'Hare","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2009.08.002_bib25","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.0600001103","article-title":"Activity of dual SRC-ABL inhibitors highlights the role of BCR\/ABL kinase dynamics in drug resistance","volume":"103","author":"Azam","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.beha.2009.08.002_bib26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/138920106778521532","article-title":"New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"7","author":"Kimura","year":"2006","journal-title":"Curr Pharm Biotechnol"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.leukres.2006.01.006","article-title":"In vivo antiproliferative effect of NS-187, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations","volume":"30","author":"Naito","year":"2006","journal-title":"Leuk Res"},{"issue":"15","key":"10.1016\/j.beha.2009.08.002_bib28","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2009.08.002_bib29","first-page":"3127","article-title":"The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Dorsey","year":"2000","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib30","first-page":"1267","article-title":"A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants","volume":"9","author":"Huron","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2009.08.002_bib31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1023789416385","article-title":"The Aurora kinases: role in cell transformation and tumorigenesis","volume":"22","author":"Katayama","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"10.1016\/j.beha.2009.08.002_bib33","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/0008-5472.CAN-04-3981","article-title":"RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells","volume":"65","author":"Hata","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2009.08.002_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2004","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/10445490050199063","article-title":"Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie1","volume":"19","author":"Hu","year":"2000","journal-title":"DNA Cell Biol"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00412-003-0265-1","article-title":"Regulation of Aurora-A kinase on the mitotic spindle","volume":"112","author":"Kufer","year":"2003","journal-title":"Chromosoma"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/1535-7163.451.3.4","article-title":"The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer","volume":"3","author":"Rojanala","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.beha.2009.08.002_bib38","first-page":"991","article-title":"Overexpression of oncogenic STK15\/BTAK\/Aurora A kinase in human pancreatic cancer","volume":"9","author":"Li","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2009.08.002_bib39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-1057-03","article-title":"Overexpression and amplification of Aurora-A in hepatocellular carcinoma","volume":"10","author":"Jeng","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2009.08.002_bib40","first-page":"1518","article-title":"Loss of aurora A\/STK15\/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast","volume":"12","author":"Hoque","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"10.1016\/j.beha.2009.08.002_bib41","first-page":"5697","article-title":"Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas","volume":"63","author":"Moreno-Bueno","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib42","first-page":"1420","article-title":"Activation and overexpression of centrosome kinase BTAK\/Aurora-A in human ovarian cancer","volume":"9","author":"Gritsko","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2009.08.002_bib43","first-page":"1275","article-title":"The putative serine\/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas","volume":"10","author":"Reichardt","year":"2003","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.beha.2009.08.002_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2141.2003.04311.x","article-title":"Aurora2\/BTAK\/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma","volume":"121","author":"Hamada","year":"2003","journal-title":"Br J Haematol"},{"issue":"6978","key":"10.1016\/j.beha.2009.08.002_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature02328","article-title":"Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle","volume":"428","author":"Dewar","year":"2004","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib46","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0960-9822(02)00848-5","article-title":"The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis","volume":"12","author":"Murata-Hori","year":"2002","journal-title":"Curr Biol"},{"issue":"1\u20132","key":"10.1016\/j.beha.2009.08.002_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/B:NEON.0000021784.33421.05","article-title":"High expression of Aurora-B\/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas","volume":"67","author":"Araki","year":"2004","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.beha.2009.08.002_bib48","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1210\/jc.2004-1518","article-title":"Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation","volume":"90","author":"Sorrentino","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beha.2009.08.002_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cm.20039","article-title":"Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells","volume":"59","author":"Sasai","year":"2004","journal-title":"Cell Motil Cytoskeleton"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib50","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1074\/jbc.274.11.7334","article-title":"Cell cycle-dependent expression and centrosome localization of a third human aurora\/Ipl1-related protein kinase, AIK3","volume":"274","author":"Kimura","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2009.08.002_bib51","article-title":"Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients AACR","author":"Papayannidis","year":"2009","journal-title":"Abstract meetings"},{"key":"10.1016\/j.beha.2009.08.002_bib52","article-title":"Aurora kinase inhibitors in the treatment of CML and Ph+ ALL patients resistant to imatinib","author":"Papayannidis","year":"2007","journal-title":"Haematologica"},{"issue":"7191","key":"10.1016\/j.beha.2009.08.002_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.08.002_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-09-112631","article-title":"Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance","author":"Iacobucci","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.08.002_bib55","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"10","key":"10.1016\/j.beha.2009.08.002_bib56","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.08.002_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-08-173963","article-title":"Identification and molecular characterisation of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukaemia patients: on behalf of GIMEMA AL WP","author":"Iacobucci","year":"2009","journal-title":"Blood Jul"},{"issue":"6","key":"10.1016\/j.beha.2009.08.002_bib58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ana.20691","article-title":"GSK3B polymorphisms alter transcription and splicing in Parkinson's disease","volume":"58","author":"Kwok","year":"2005","journal-title":"Ann Neurol"},{"issue":"7239","key":"10.1016\/j.beha.2009.08.002_bib59","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.beha.2009.08.002_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1358\/dnp.2003.16.10.829296","article-title":"Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma","volume":"16","author":"Williams","year":"2003","journal-title":"Drug News Perspect"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T19:11:50Z","timestamp":1685214710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000577"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.08.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}